Phase1, STP7 Cocaine Drug-Drug Interaction Study
Key facts
- Who runs it
- Stalicla SA
- Where
- Overland Park, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 21 people enrolled
- Started
- 15 Apr 2024
- Ended
- 7 Oct 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- STP7 (mavoglurant)
- Placebo
- Cocaine Hydrochloride
- Record updated
- 23 April 2026
Who can take part
- Age
- 18 years to 59 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Be participants who are cocaine-experienced and not seeking treatment for cocaine use disorder
- Males and females between 18 and 59 years of age, inclusive
- Have a body mass index (BMI) within a range of 17.0 to 36.0 kg/m2 and a minimum weight of at least 50.0 kg at screening
- Have experience using cocaine by the smoked or i.v. route at least 6 times in the past 12 months prior to clinic intake (Day -3) and at least one use (smoked, i.v., or nasal route) within the past 3 months
- Provide a urine sample positive for cocaine at least once during screening (Days -28 to -4)
- Be able to verbalize understanding of consent form, able to provide written informed consent, and verbalize willingness to complete study procedures
- A female study participant must meet one of the following criteria:; If of childbearing potential - agrees to use one of the accepted contraceptive regimens from at least 30 days prior to the first administration of the study medication, during the study, and for at least 30 days after the last dose of the study medication. An acceptable method of contraception includes one of the following:; Abstinence from heterosexual intercourse ii. Hormonal contraceptives (injectable/implant/insertable hormonal birth control products, transdermal patch) iii. Intrauterine device (with or without hormones) OR agrees to use a double barrier method (e.g. condom and spermicide) during the study and for at least 30 days after the last dose of the study medication. If a female of non-childbearing potential - should be surgically sterile (i.e. has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation/occlusion) or in a menopausal state (at least 1 year without menses), as confirmed by FSH levels; A male study participant that engages in sexual activity that has the risk of pregnancy must agree to use a double barrier method (e.g. condom and spermicide) and agree to not donate sperm during the study and for at least 90 days after the last dose of the study medication
- Be able to comply with protocol requirements, rules and regulations of the study site, and be likely to complete all the study treatments
Who cannot take part
- Have any previous medically adverse reaction to cocaine, including loss of consciousness, chest pain, paranoid reaction or seizure
- Blood donation (excluding plasma donation) of approximately 500 mL within 56 days prior to screening
- Plasma donation within 7 days prior to screening
- Treatment with an investigational drug within 30 days or 5 times the half-life (whichever is longer) prior to screening
- Have a positive urine drug screen upon clinic intake (Day -3) for any of the following drugs: alcohol, amphetamine/methamphetamine, barbiturates, benzodiazepines, buprenorphine, cocaine, fentanyl, 3,4 methylenedioxymethamphetamine (MDMA), methadone, phencyclidine/phenylcyclohexyl piperidine (PCP), propoxyphene, and opioids (e.g., codeine, heroin, morphine, oxycodone, etc.)
- Have used any prescription drugs within 14 days of clinic intake or non-prescription drugs or herbal remedies within 7 days of clinic intake
- Have positive results for a coronavirus disease 2019 (COVID-19) test performed after screening is complete and participant is confirmed, but prior to admission
- Have a current or past history of seizure disorder, including alcohol- or stimulant-related seizure, febrile seizure, or significant family history of idiopathic seizure disorder
- Have a sitting systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg and heart rate > 100 beats per minute at screening and clinic intake
- Have a history of suicide attempts or current or recent evidence of suicidal ideation in the past 12 months based on the Columbia-Suicide Severity Rating Scale
- Have a positive serology for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCVab), or human immunodeficiency virus (HIV)
- Have a history of liver disease or current elevation of liver function test (LFT) values as follows:; aspartate aminotransferase (AST) >2x the upper limit of normal; alanine aminotransferase (ALT) >2 × the upper limit of normal
- Have a history of renal disease or current renal function test values as follows:; blood urea nitrogen (BUN) >2× ULN, or; creatinine >1.5 mg/dL
- Have any clinically significant finding on medical history, physical examination, clinical laboratory test, vital signs or ECGs that contraindicate participation in the study
- Have clinically significant findings in the opinion of an investigator based on the MINI (version 7.0) neuropsychiatric interview
- Be pregnant or lactating
- Have consumed grapefruit or other foods that inhibit or induce CYP3A4 within 7 days of Study Day 1
- Be unable to distinguish between a 20 mg and 40 mg dose of cocaine i.v. based on the high effects VAS at either the 5 or 10 minute time point during the screening infusion
Where in United States
- Altasciences Clinical KansasOverland Park, United States
About the trial
What the trial wants to find out
This is a double-blind, placebo-controlled, parallel group study to compare the effects of STP7 (mavoglurant) vs placebo control on i.v. cocaine's physiological and subjective effects in non-treatment seeking, cocaine-experienced males or females participants between 18 and 59 years of age.
Read full original descriptionShow less
The primary objective of this study is to determine if there are clinically meaningful interactions between oral STP7 (mavoglurant) treatment concurrent with 20 and 40 mg i.v. cocaine infusions by measuring adverse events and cardiovascular responses including heart rate, blood pressure, and electrocardiogram (including corrected QT interval).
The secondary objectives are:
* To evaluate whether administration of STP7 (mavoglurant) alters the pharmacokinetics of cocaine and/or its major metabolite, benzoylecgonine. * To determine the pharmacokinetic of STP7 (mavoglurant) administered at a dose of 200 mg twice a day. * To evaluate whether STP7 (mavoglurant) treatment alters the subjective effects of cocaine measured by Visual Analog Scales (VAS) and Brief Substance Craving Scale (BSCS).
The 2 groups in the trial
- STP7 (mavoglurant) modified release film-coated tabletTreatment being tested
Participants will take STP7 (mavoglurant) twice a day (BID) from Days 3 to 9 according to the following dosing schedule: * Day 3: 50 mg BID; * Day 4: 100 mg BID; * Days 5-9: 200 mg BID, * Day 10: 200 mg only the morning dose. Morning STP7 (mavoglurant) doses must be taken within 30 minutes of beginning a meal.
Treatment: STP7 (mavoglurant) and Cocaine Hydrochloride
- PlaceboPlacebo, for comparison
Participants will take matched placebo twice a day (BID) from Days 3 to 9 and only the morning dose on Day 10. Morning Placebo must be taken within 30 minutes of beginning a meal.
Treatment: Placebo and Cocaine Hydrochloride
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 1, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess Potential Interactions Between Intravenous Cocaine and Oral STP7
- Record updated
- 23 April 2026